Collegium Pharmaceutical Income Statement (2014-2026) | COLL

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	82.94M	78.84M	38.33M	3.63M	123.55M	127.01M	129.62M	144.77M	135.55M	136.71M	149.75M	144.92M	145.28M	7.96M	181.95M	177.76M	188.00M	209.36M	205.45M	193.52M
Cost of Revenue (Quarter)	32.70M	15.93M	28.70M	35.26M	33.68M	30.62M	79.83M	67.36M	24.26M	56.40M	20.60M	53.47M	19.95M	62.51M	28.19M	24.96M	79.62M	24.72M	21.60M	20.80M
Gross Profit (Quarter)	50.24M	46.11M	-1.33M	48.50M	52.36M	58.84M	49.79M	77.40M	73.83M	80.31M	94.63M	91.46M	90.81M	96.79M	98.29M	97.32M	108.38M	129.17M	128.38M	117.25M
Operating items
Amortization - Intangibles (Quarter)	16.80M	16.80M	16.80M	18.92M	37.50M	37.55M	42.28M	37.47M	37.46M	36.32M	34.51M	34.52M	34.52M	40.80M	55.47M	55.47M	55.47M	55.47M	55.47M	55.47M
Depreciation & Amortization - Total (Quarter)																1.09M				0.46M
Research & Development (Quarter)	3.46M	1.45M	1.61M	3.98M
Selling, General & Administrative (Quarter)	30.37M	30.51M	26.60M	54.53M	41.25M	38.37M	38.03M	52.77M	38.19M	35.30M	32.94M	41.98M	43.34M	61.95M	63.09M	76.42M	73.64M	67.10M	67.64M	86.35M
Restructuring Costs (Quarter)			4.58M									8.62M	7.81M	7.80M	9.47M	13.29M	9.80M	10.90M
Other Operating Expenses (Quarter)										11.57M	-206.99M	-8.62M	-7.81M	5.39M	-51.77M	-15.17M	-10.16M	-10.92M	-0.02M	-0.46M
Operating Expenses (Quarter)	33.83M	31.96M	32.79M	58.51M	41.25M	38.37M	38.03M	52.77M	38.19M	35.30M	32.94M	41.98M	43.34M	61.95M	60.18M	75.64M	73.28M	67.08M	67.62M	86.35M
Operating Income (Quarter)	16.41M	14.15M	-34.12M	-10.02M	11.11M	20.47M	11.76M	24.63M	35.63M	45.01M	61.69M	49.47M	47.47M	34.84M	38.11M	21.69M	35.10M	62.09M	60.76M	30.90M
EBIT (Quarter)	16.41M	14.15M	-34.12M	-10.02M	11.11M	20.47M	11.76M	24.63M	35.63M	45.01M	61.69M	49.47M	47.47M	34.84M	38.11M	21.69M	35.10M	62.09M	60.76M	30.90M
Non-operating items
Interest & Investment Income (Quarter)	0.00M	0.00M	0.00M	0.00M	0.01M	0.01M	1.03M	2.75M	4.03M	4.54M	4.30M	4.49M	4.40M	3.28M	1.81M	2.23M	2.38M	3.12M	3.56M	3.71M
Other Non Operating Income (Quarter)								23.50M	-47.01M				-7.18M	-4.14M					-15.99M
Non Operating Income (Quarter)
Net income details
EBT (Quarter)	10.99M	9.04M	-38.88M	-15.84M	-6.65M	1.43M	-7.79M	-17.56M	17.80M	28.78M	46.71M	36.62M	29.10M	15.58M	17.27M	3.12M	17.02M	43.44M	29.04M	18.74M
Tax Provisions (Quarter)	-61.85M	0.99M	-13.84M	-2.77M	-1.46M	0.97M	-0.59M	-0.13M	4.79M	8.15M	14.77M	8.91M	9.49M	6.25M	4.73M	0.70M	5.04M	11.93M	12.07M	4.24M
Profit After Tax (Quarter)	72.84M	8.05M	-25.03M	-13.07M	-5.19M	0.46M	-7.20M	-17.43M	13.01M	20.63M	31.94M	27.71M	19.61M	9.34M	12.54M	2.42M	11.98M	31.51M	16.96M	14.50M
Income from Continuing Operations (Quarter)	72.84M	8.05M	-25.03M	-13.07M	-5.19M	0.46M	-7.20M	-17.43M	13.01M	20.63M	31.94M	27.71M	19.61M	9.34M	12.54M	2.42M	11.98M	31.51M	16.96M	14.50M
Consolidated Net Income (Quarter)	72.84M	8.05M	-25.03M	-13.07M	-5.19M	0.46M	-7.20M	-17.43M	13.01M	20.63M	31.94M	27.71M	19.61M	9.34M	12.54M	2.42M	11.98M	31.51M	16.96M	14.50M
Income towards Parent Company (Quarter)	72.84M	8.05M	-25.03M	-13.07M	-5.19M	0.46M	-7.20M	-17.43M	13.01M	20.63M	31.94M	27.71M	19.61M	9.34M	12.54M	2.42M	11.98M	31.51M	16.96M	14.50M
Net Income towards Common Stockholders (Quarter)	74.01M	8.05M	-25.03M	-13.07M	-5.19M	0.46M	-7.20M	-17.43M	13.01M	20.63M	31.94M	27.71M	19.61M	9.34M	12.54M	2.42M	11.98M	31.51M	16.96M	14.50M
Additional items
EPS (Basic) (Quarter)	2.06	0.23	-0.73	-0.39	-0.15	0.01	-0.21	-0.51	0.38	0.61	0.99	0.86	0.60	0.29	0.39	0.08	0.38	1.00	0.54	0.45
EPS (Weighted Average and Diluted) (Quarter)	1.79	0.22	-0.73	-0.39	-0.15	0.01	-0.21	-0.51	0.34	0.53	0.82	0.71	0.52	0.27	0.36	0.07	0.34	0.84	0.46	0.40
Shares Outstanding (Weighted Average) (Quarter)	35.30M	35.37M	34.94M	33.67M	34.00M	34.06M	33.83M	34.32M	34.62M	33.74M	33.74M	32.33M	32.43M	32.26M	32.27M	31.79M	31.81M	31.57M	31.71M	32.09M
Shares Outstanding (Diluted Average) (Quarter)											41.79M	41.44M	40.38M	40.16M	40.42M	32.84M	39.08M	39.44M	40.08M	40.07M
EBITDA (Quarter)	16.41M	14.15M	-34.12M	-10.02M	11.11M	20.47M	11.76M	24.63M	35.63M	45.01M	61.69M	49.47M	47.47M	34.84M	38.11M	22.78M	35.10M	62.09M	60.76M	31.36M
Interest Expenses (Quarter)	5.42M	5.12M	4.76M	5.83M	17.76M	19.05M	20.57M	21.43M	21.86M	20.77M	19.28M	17.34M	15.59M	18.39M	22.65M	20.79M	20.46M	21.77M	19.29M	15.86M
Tax Rate (Quarter)	-562.75%	10.97%	35.61%	17.50%	21.89%	68.09%	7.60%	0.75%	26.91%	28.31%	31.62%	24.33%	32.62%	40.08%	27.41%	22.58%	29.62%	27.46%	41.58%	22.65%

Research Tools

Collegium Pharmaceutical Income Statement (2014-2026) | COLL

Create an account

Sign In

Reset Password